The Daily Dose: IBS Phenotypes
Your daily dose of clinical news from Patient Care Online.
COVID-19 Vaccines, Boosters, Prior Infection Significantly Reduce Risks, but Immunity Wanes
A large cohort study confirms the observed efficacy of initial and follow-up COVID-19 vaccination and prior infection against infection, hospitalization, and death.
The Daily Dose from Patient Care Online: October 12, 2022
Irritable Bowel Syndrome Cohort Analysis Identifies 7 Distinct Latent Subsets
Identification of unique IBS subsets has implications for more individualized treatment as well as approaches to clinical trials, say study authors.
Cardiometabolic Disease Update: 12 Studies
Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.
Remdesivir for Severe COVID-19: Expert Guidance on Use in Clinical Practice
Elizabeth Sapey, PhD, discusses how the updated treatment recommendations from the World Health Organization may impact future use of remdesivir.
The Daily Dose from Patient Care Online: October 11, 2022
Weight Loss is Essential to Optimize Type 2 Diabetes Treatment Management
Weight loss of at least 5% to 10% for persons with T2D is realistic and essential, says Nisa Maruthur, MD, MHS, coauthor of the new ADA/EASD consensus report.
Americans Have not Been Truthful about Following COVID-19 Precautions
More than 4 in 10 US adults have either misrepresented their COVID-19 status or failed to adhere to public health measures. A new survey found out why.
Ustekinumab Demonstrates Sustained Clinical, Corticosteroid-free Remission at 4 Years in Adults with Moderate-to-Severe Ulcerative Colitis
Over half of induction responder patients who received ustekinumab at maintenance baseline were in symptomatic remission 4 years later, according to data presented at UEG Week 2022.
ADA/EASD Consensus Report on T2D Management: Coauthor Talks Take-homes for Primary Care
Nisa Maruthur, MD, MHS, a primary care physician and consensus report coauthor, discusses elements of the most effective care for patients with type 2 diabetes (T2D).
Remdesivir for Treatment of Severe COVID-19: Expert Reviews Latest Evidence
Elizabeth Sapey, PhD, discusses findings from the SOLIDARITY study and similar research on the efficacy of remdesivir for treatment of severe disease.
Simple Primary Care Screening Tool Predicts Asthma Diagnosis in Preschoolers
The noninvasive, easily administered tool was able to predict at age 3 years children who would be diagnosed with asthma at age 5 years.
Clinical Practice Guidelines Could be More Primary Care-friendly, says Nisa Maruthur, MD, MHS
Dr Maruthur, a PCP and coauthor for the new ADA/EASD consensus report on T2D, says that's why this report includes the "tips on implementation" sections.
4 New Drugs Approved for Primary Care: Q3 2022
Novel NMDA receptor antagonist approved for the treatment of major depressive disorder, first topical PDE4i approved for plaque psoriasis, and more.
ADA/EASD Calls for Wide Systemic Change to Address Impact of Social Determinants of Health
As long as the role of social determinants of health in T2D is not prioritized, care for these patients will remain poor and outcomes will not improve, says consensus report author.
Are the Southern Hemisphere's High Influenza Rates a Warning for the North This Year?
Influenza rates were higher in Australia during the April-October season this year than they have been in 5 years. Should we be preparing now?
FDA Grants Fast Track Designation to Tirzepatide for Treatment of Obesity, Overweight in Adults
The first-in-class dual incretin receptor agonist was granted fast track designation for investigation in adults with obesity or overweight with weight-related comorbidities.
Candy, Pastries a Gateway to Higher Unhealthy Food Intake among Adolescents, New Study Finds
Findings show that increased consumption of candy among adolescents was linked to a 31% increase in intake of all other ultraprocessed foods.
SGLT-2 Inhibitors, GLP-1 Receptor Agonists not Cost-effective as First-Line T2D Therapy
When modeled as first-line therapy vs metformin, treatment benefit was significantly outweighed by cost for both classes.
